EE200200211A - Bitsüklilised aminohapped kui farmatseutilised toimeained - Google Patents

Bitsüklilised aminohapped kui farmatseutilised toimeained

Info

Publication number: EE200200211A
Authority: EE; Estonia
Prior art keywords: amino acids; active ingredients; pharmaceutical active; bicyclic amino; bicyclic
Prior art date: 1999-10-20

Application number

EEP200200211A

Other languages

English (en)

Estonian (et)

Inventor

Stephen Bryans Justin

Clive Blakemore David

Osborne Simon

Receveur Jean-Marie

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-20

Filing date

2000-10-17

Publication date

2003-06-16

2000-10-17 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

2003-06-16 Publication of EE200200211A publication Critical patent/EE200200211A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)

EEP200200211A 1999-10-20 2000-10-17 Bitsüklilised aminohapped kui farmatseutilised toimeained EE200200211A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16072599P	1999-10-20	1999-10-20
PCT/US2000/028687 WO2001028978A1 (en)	1999-10-20	2000-10-17	Bicyclic amino acids as pharmaceutical agents

Publications (1)

Publication Number	Publication Date
EE200200211A true EE200200211A (et)	2003-06-16

Family

ID=22578159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200211A EE200200211A (et)	1999-10-20	2000-10-17	Bitsüklilised aminohapped kui farmatseutilised toimeained

Country Status (50)

Country	Link
US (2)	US6689906B1 (xx)
EP (2)	EP1506955B1 (xx)
JP (2)	JP3632191B2 (xx)
KR (2)	KR100593349B1 (xx)
CN (1)	CN1165518C (xx)
AP (2)	AP2002002517A0 (xx)
AR (2)	AR026087A1 (xx)
AT (2)	ATE293590T1 (xx)
AU (2)	AU778871B2 (xx)
BG (2)	BG106719A (xx)
BR (1)	BR0014972B1 (xx)
CA (1)	CA2386297C (xx)
CO (1)	CO5280060A1 (xx)
CR (1)	CR6620A (xx)
CU (1)	CU23112A3 (xx)
CZ (1)	CZ295960B6 (xx)
DE (2)	DE60019628T2 (xx)
DO (1)	DOP2000000083A (xx)
DZ (1)	DZ3197A1 (xx)
EA (1)	EA005206B1 (xx)
EC (1)	ECSP045393A (xx)
EE (1)	EE200200211A (xx)
ES (2)	ES2282785T3 (xx)
GE (1)	GEP20043297B (xx)
GT (2)	GT200000183AA (xx)
HK (1)	HK1049826B (xx)
HN (1)	HN2000000224A (xx)
HR (2)	HRP20040709A2 (xx)
HU (1)	HUP0203325A3 (xx)
IL (3)	IL149143A0 (xx)
IS (2)	IS6348A (xx)
MA (1)	MA26842A1 (xx)
MX (1)	MXPA02003229A (xx)
MY (1)	MY127678A (xx)
NO (2)	NO20021780D0 (xx)
NZ (1)	NZ517961A (xx)
OA (1)	OA12070A (xx)
PA (1)	PA8505201A1 (xx)
PE (1)	PE20010740A1 (xx)
PL (1)	PL354607A1 (xx)
PT (1)	PT1226110E (xx)
SI (1)	SI1226110T1 (xx)
SK (1)	SK5232002A3 (xx)
SV (1)	SV2001000188A (xx)
TR (2)	TR200500221T2 (xx)
TW (2)	TW200505824A (xx)
UA (1)	UA72931C2 (xx)
WO (1)	WO2001028978A1 (xx)
YU (2)	YU29302A (xx)
ZA (1)	ZA200202543B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
ATE390133T1 (de) *	2000-06-26	2008-04-15	Warner Lambert Co	Gabapentinanaloga für schlafstörungen
US6620829B2 (en)	2000-10-17	2003-09-16	Warner-Lambert Company	Method of treating noninflammatory cartilage damage
EP1226820A1 (en) *	2001-01-26	2002-07-31	Warner-Lambert Company	Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
ATE460392T1 (de)	2001-04-19	2010-03-15	Warner Lambert Co	Kondensierte bizyklische oder trizyklische aminosäuren
GB2375108A (en) *	2001-05-04	2002-11-06	Warner Lambert Co	Production of a bicycloheptanone
GB2375109A (en) *	2001-05-04	2002-11-06	Warner Lambert Co	Process for preparing bicyclic amino acid
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
PT1404324E (pt) *	2001-06-11	2008-03-05	Xenoport Inc	Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2474000A1 (en)	2002-01-31	2003-08-07	Warner-Lambert Company Llc	Alpha 2 delta ligands to treat tinnitus
WO2003070237A1 (en) *	2002-02-22	2003-08-28	Warner-Lambert Company Llc	Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2004002462A2 (en) *	2002-06-27	2004-01-08	Warner-Lambert Company Llc	Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
GB0219024D0 (en) *	2002-08-15	2002-09-25	Pfizer Ltd	Synergistic combinations
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
JP2005539092A (ja) *	2002-08-15	2005-12-22	ファイザー・インク	縮合二環式または三環式アミノ酸の治療における使用
US7018818B2 (en)	2002-10-04	2006-03-28	Pfizer Inc.	Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en)	2002-10-04	2002-11-13	Pfizer Ltd	Cyclic nitromethyl acetic acid derivatives
US7060727B2 (en)	2002-12-11	2006-06-13	Xenoport, Inc.	Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
EP2172197A1 (en)	2002-12-13	2010-04-07	Warner-Lambert Company LLC	Octanoic acid derivative to treat fibromyalgia and other pains
NZ567457A (en)	2002-12-13	2009-08-28	Warner Lambert Co	Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
MXPA06002789A (es)	2003-09-12	2006-06-14	Pfizer	Combinaciones que comprenden ligandos alfa-2-delta.
WO2006092692A1 (en) *	2005-03-01	2006-09-08	Pfizer Limited	Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) *	2006-06-30	2008-09-17	Pfizer Prod Inc	Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN102058885B (zh)	2006-12-22	2013-04-10	瑞蔻达蒂爱尔兰有限公司	采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
JP4479974B2 (ja)	2007-09-28	2010-06-09	第一三共株式会社	二環性γ−アミノ酸誘導体
WO2010110361A1 (ja)	2009-03-26	2010-09-30	第一三共株式会社	二環性γ－アミノ酸誘導体の製造方法
WO2012169474A1 (ja)	2011-06-08	2012-12-13	第一三共株式会社	イミニウム塩を経由する二環性化合物の製造方法
CN103562170B (zh)	2011-06-08	2015-09-02	第一三共株式会社	经由克莱森重排制备双环化合物的方法
CA2859003C (en)	2011-12-15	2016-11-01	Daiichi Sankyo Company, Limited	Optical resolution method for bicyclic compound using asymmetric catalyst
WO2013154066A1 (ja)	2012-04-10	2013-10-17	第一三共株式会社	酵素を用いる二環性化合物の光学分割方法
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
TWI635071B (zh)	2013-07-08	2018-09-11	第一三共股份有限公司	光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en)	2017-03-16	2018-09-20	Basf Se	Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) *	2021-03-29	2021-06-29	华东理工大学	一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3641129A (en)	1969-06-17	1972-02-08	Merck & Co Inc	Antifibrinolytic compounds
DE2460891C2 (de)	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) *	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
CU23048A3 (es)	1997-10-27	2005-06-24	Warner Lambert Co	Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos

2000
- 2000-10-05 HN HN2000000224A patent/HN2000000224A/es unknown
- 2000-10-06 SV SV2000000188A patent/SV2001000188A/es not_active Application Discontinuation
- 2000-10-17 IL IL14914300A patent/IL149143A0/xx not_active IP Right Cessation
- 2000-10-17 KR KR1020027005036A patent/KR100593349B1/ko not_active Expired - Fee Related
- 2000-10-17 MX MXPA02003229A patent/MXPA02003229A/es active IP Right Grant
- 2000-10-17 DE DE60019628T patent/DE60019628T2/de not_active Expired - Lifetime
- 2000-10-17 UA UA2002032434A patent/UA72931C2/uk unknown
- 2000-10-17 EE EEP200200211A patent/EE200200211A/xx unknown
- 2000-10-17 AU AU10920/01A patent/AU778871B2/en not_active Ceased
- 2000-10-17 PL PL00354607A patent/PL354607A1/xx not_active Application Discontinuation
- 2000-10-17 CN CNB008145644A patent/CN1165518C/zh not_active Expired - Fee Related
- 2000-10-17 ES ES04027485T patent/ES2282785T3/es not_active Expired - Lifetime
- 2000-10-17 IL IL16406000A patent/IL164060A0/xx unknown
- 2000-10-17 CZ CZ20021310A patent/CZ295960B6/cs not_active IP Right Cessation
- 2000-10-17 JP JP2001531783A patent/JP3632191B2/ja not_active Expired - Fee Related
- 2000-10-17 AP APAP/P/2002/002517A patent/AP2002002517A0/en unknown
- 2000-10-17 OA OA1200200117A patent/OA12070A/en unknown
- 2000-10-17 CA CA2386297A patent/CA2386297C/en not_active Expired - Fee Related
- 2000-10-17 HU HU0203325A patent/HUP0203325A3/hu unknown
- 2000-10-17 ES ES00972226T patent/ES2237464T3/es not_active Expired - Lifetime
- 2000-10-17 AT AT00972226T patent/ATE293590T1/de not_active IP Right Cessation
- 2000-10-17 HK HK03101868.4A patent/HK1049826B/zh not_active IP Right Cessation
- 2000-10-17 EP EP04027485A patent/EP1506955B1/en not_active Expired - Lifetime
- 2000-10-17 TR TR2005/00221T patent/TR200500221T2/xx unknown
- 2000-10-17 DE DE60034157T patent/DE60034157T2/de not_active Expired - Lifetime
- 2000-10-17 PT PT00972226T patent/PT1226110E/pt unknown
- 2000-10-17 BR BRPI0014972-1A patent/BR0014972B1/pt not_active IP Right Cessation
- 2000-10-17 YU YU29302A patent/YU29302A/sh unknown
- 2000-10-17 WO PCT/US2000/028687 patent/WO2001028978A1/en not_active Ceased
- 2000-10-17 NZ NZ517961A patent/NZ517961A/xx unknown
- 2000-10-17 EA EA200200293A patent/EA005206B1/ru unknown
- 2000-10-17 GE GE4783A patent/GEP20043297B/en unknown
- 2000-10-17 HR HRP20040709 patent/HRP20040709A2/xx not_active Application Discontinuation
- 2000-10-17 SI SI200030670T patent/SI1226110T1/xx unknown
- 2000-10-17 AT AT04027485T patent/ATE358116T1/de not_active IP Right Cessation
- 2000-10-17 HR HR20020428A patent/HRP20020428B1/xx not_active IP Right Cessation
- 2000-10-17 KR KR1020067002249A patent/KR100566462B1/ko not_active Expired - Fee Related
- 2000-10-17 TR TR2002/01094T patent/TR200201094T2/xx unknown
- 2000-10-17 EP EP00972226A patent/EP1226110B1/en not_active Expired - Lifetime
- 2000-10-17 AP AP2004003186A patent/AP2004003186A0/xx unknown
- 2000-10-17 SK SK523-2002A patent/SK5232002A3/sk unknown
- 2000-10-17 YU YU73004A patent/YU73004A/sh unknown
- 2000-10-17 US US10/130,023 patent/US6689906B1/en not_active Expired - Fee Related
- 2000-10-17 DZ DZ003197A patent/DZ3197A1/xx active
- 2000-10-18 MY MYPI20004896A patent/MY127678A/en unknown
- 2000-10-18 PA PA20008505201A patent/PA8505201A1/es unknown
- 2000-10-19 AR ARP000105497A patent/AR026087A1/es unknown
- 2000-10-19 GT GT200000183AK patent/GT200000183AA/es unknown
- 2000-10-19 DO DO2000000083A patent/DOP2000000083A/es unknown
- 2000-10-19 CO CO00079741A patent/CO5280060A1/es not_active Application Discontinuation
- 2000-10-19 GT GT200000183A patent/GT200000183A/es unknown
- 2000-10-19 PE PE2000001116A patent/PE20010740A1/es not_active Application Discontinuation
- 2000-10-20 TW TW093125953A patent/TW200505824A/zh unknown
- 2000-10-20 TW TW089122115A patent/TWI225855B/zh not_active IP Right Cessation
2002
- 2002-03-28 ZA ZA200202543A patent/ZA200202543B/xx unknown
- 2002-04-15 IL IL149143A patent/IL149143A/en unknown
- 2002-04-16 CU CU78A patent/CU23112A3/es unknown
- 2002-04-16 NO NO20021780A patent/NO20021780D0/no not_active Application Discontinuation
- 2002-04-17 IS IS6348A patent/IS6348A/is unknown
- 2002-04-18 CR CR6620A patent/CR6620A/es not_active Application Discontinuation
- 2002-05-10 MA MA26634A patent/MA26842A1/fr unknown
- 2002-05-20 BG BG106719A patent/BG106719A/bg unknown
- 2002-05-20 BG BG108860A patent/BG108860A/en unknown
2004
- 2004-01-21 US US10/762,026 patent/US6835751B2/en not_active Expired - Fee Related
- 2004-07-28 EC EC2004005393A patent/ECSP045393A/es unknown
- 2004-08-17 AR ARP040102937A patent/AR045456A2/es unknown
- 2004-09-01 NO NO20043663A patent/NO20043663L/no not_active Application Discontinuation
- 2004-09-14 JP JP2004266488A patent/JP3744928B2/ja not_active Expired - Fee Related
- 2004-10-08 IS IS7497A patent/IS7497A/is unknown
2005
- 2005-03-23 AU AU2005201268A patent/AU2005201268A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20060013701A (ko)	2006-02-13
CR6620A (es)	2004-02-02
YU73004A (sh)	2005-11-28
HK1049826B (zh)	2005-02-25
CU23112A3 (es)	2006-02-27
AR045456A2 (es)	2005-10-26
AU1092001A (en)	2001-04-30
HRP20020428A2 (en)	2005-02-28
NO20043663L (no)	2002-04-16
SV2001000188A (es)	2001-09-07
ES2282785T3 (es)	2007-10-16
WO2001028978A1 (en)	2001-04-26
JP2003512348A (ja)	2003-04-02
DE60019628T2 (de)	2006-01-19
CN1165518C (zh)	2004-09-08
SI1226110T1 (en)	2005-08-31
UA72931C2 (uk)	2005-05-16
EA005206B1 (ru)	2004-12-30
US6835751B2 (en)	2004-12-28
TR200500221T2 (tr)	2005-03-21
HRP20040709A2 (en)	2004-12-31
AR026087A1 (es)	2002-12-26
EP1226110A1 (en)	2002-07-31
MXPA02003229A (es)	2002-09-30
ECSP045393A (es)	2004-10-23
EP1506955B1 (en)	2007-03-28
GEP20043297B (en)	2004-01-12
GT200000183A (es)	2000-10-19
OA12070A (en)	2003-11-10
US6689906B1 (en)	2004-02-10
BG108860A (en)	2006-03-31
SK5232002A3 (en)	2003-07-01
EA200200293A1 (ru)	2002-10-31
IL149143A (en)	2007-02-11
KR100593349B1 (ko)	2006-06-26
EP1506955A1 (en)	2005-02-16
TWI225855B (en)	2005-01-01
TR200201094T2 (tr)	2002-09-23
YU29302A (sh)	2005-06-10
AP2002002517A0 (en)	2002-06-30
ES2237464T3 (es)	2005-08-01
BR0014972A (pt)	2002-07-16
CZ295960B6 (cs)	2005-12-14
ATE358116T1 (de)	2007-04-15
AU778871B2 (en)	2004-12-23
HN2000000224A (es)	2001-04-11
IL149143A0 (en)	2002-11-10
HK1049826A1 (en)	2003-05-30
US20040152779A1 (en)	2004-08-05
CN1382118A (zh)	2002-11-27
KR100566462B1 (ko)	2006-03-31
CA2386297C (en)	2010-02-09
HRP20020428B1 (en)	2006-02-28
DE60034157D1 (de)	2007-05-10
BG106719A (bg)	2003-02-28
IS7497A (is)	2004-10-08
EP1226110B1 (en)	2005-04-20
JP3632191B2 (ja)	2005-03-23
NO20021780L (no)	2002-04-16
JP3744928B2 (ja)	2006-02-15
NO20021780D0 (no)	2002-04-16
MA26842A1 (fr)	2004-12-20
PL354607A1 (en)	2004-01-26
CA2386297A1 (en)	2001-04-26
CZ20021310A3 (cs)	2003-05-14
DE60034157T2 (de)	2007-12-13
IS6348A (is)	2002-04-17
IL164060A0 (en)	2005-12-18
GT200000183AA (es)	2005-06-17
ZA200202543B (en)	2003-09-23
DOP2000000083A (es)	2002-03-30
AP2004003186A0 (en)	2004-12-31
HUP0203325A3 (en)	2003-12-29
TW200505824A (en)	2005-02-16
BR0014972B1 (pt)	2011-09-06
NZ517961A (en)	2002-12-20
AU2005201268A1 (en)	2005-04-21
CO5280060A1 (es)	2003-05-30
KR20020040900A (ko)	2002-05-30
HUP0203325A2 (hu)	2003-02-28
DZ3197A1 (fr)	2001-04-26
PA8505201A1 (es)	2002-08-29
ATE293590T1 (de)	2005-05-15
JP2005036009A (ja)	2005-02-10
MY127678A (en)	2006-12-29
DE60019628D1 (de)	2005-05-25
PE20010740A1 (es)	2001-07-27
PT1226110E (pt)	2005-07-29

Publication	Publication Date	Title
EE200200211A (et)	2003-06-16	Bitsüklilised aminohapped kui farmatseutilised toimeained
HUP0004310A3 (en)	2001-11-28	Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
PL351526A1 (en)	2003-05-05	Pharmaceutical formulation comprising amoxycillin
NO20015175D0 (no)	2001-10-23	Farmasöytisk sammensetning
EE200100259A (et)	2002-12-16	Moksifloksatsiini farmatseutiline preparaat
FIU20000164U0 (fi)	2000-04-11	Uusi farmaseuttinen formulaatio
GB0012850D0 (en)	2000-07-19	Cyclic amino acid derivatives useful as pharmaceutical agents
DK0941075T3 (da)	2003-07-14	Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
DK1183026T3 (da)	2006-11-06	Forbedrede farmaceutiske formuleringer omfattende ritonavir
HUP0102369A3 (en)	2002-05-28	Amino acid derivatives and drugs containing the same as the active ingredient
PL349393A1 (en)	2002-07-15	Sulphonyloxazolamines as therapeutic active ingredients
EP1311239A4 (en)	2005-06-22	ORAL PEPTIDE ADMINISTRATION
HUP0203226A3 (en)	2003-12-29	Pharmaceutical composition comprising benzamide derivative as active ingredient
FI4488U1 (fi)	2000-07-20	Farmaseuttinen koostumus
AR025867A1 (es)	2002-12-18	Formulacion portasdora farmaceutica
NO20004816D0 (no)	2000-09-26	Ny farmasøytisk formulering
NO20021036D0 (no)	2002-03-01	Farmasöytisk preparat
HU0402095D0 (en)	2005-01-28	Bicyclic amino acids as pharmaceutically active ingredients
SE9901967D0 (sv)	1999-05-31	New solid dosage formulation
SI1155014T1 (en)	2003-12-31	New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them